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Availability of high quality synthetic mRNAs (syn-mRNAs) has enabled progress in their applications.
Important structural features and quality requirements are discussed. Developments in the application
of mRNA-mediated manipulation of cells are presented (i) mRNA-directed expression of antigens in
dendritic cells for vaccination projects in oncogenesis, infectious disease and allergy prevention; (ii)
reprogramming of human fibroblasts to induced pluripotent stem cells with their subsequent
differentiation to the desired cell type; (iii) applications in gene therapy.Introduction
Conventional approaches for engineered changes in cellular ex-
pression profiles employ mostly DNA or RNA based viral and non-
viral vectors. But these methods carry high risks, due to genomic
integration with permanent genetic alteration of cells, and safety
and ethical concerns have been raised against the use of DNA-
based vectors in human clinical therapy. Employment of in vitro
synthesized mRNAs is an advantage if these crucial permanent
changes are not needed and the associated problems can be
avoided in applications if transient gene expression changes are
sufficient or even an advantage. Contrarily, concerns about RNA
degradation problems have halted widespread use. Recent
advances in the availability of synthetic mRNAs (syn-mRNAs) have
increased confidence in working with syn-mRNAs and this over-
view presents important features of these molecules and their
potential in multiple application fields.
The field is presented in two recent reviews: Bernal [1] presents
the different DNA- and RNA-based technologies for cellular repro-
gramming and cellular lineage-conversion with their potential
clinical applications, whereas Li et al. [2] focus on mRNA technol-
ogy; in addition to the positive aspects, they also point out some
crucial issues, such as selection pressure for cells that are deficientCorresponding author:. Krupp, G. (krupp@amp-tec.com)
http://dx.doi.org/10.1016/j.nbt.2014.04.008 
1871-6784/ 2014 Elsevier B.V.  Open access under CC BY-NC-ND license.in innate immune response and possible accumulation of muta-
tions in tumor suppressor genes.
Advantages of synthetic mRNAs (syn-mRNAs)
Although Wolff et al. [3] have shown already in 1990 that direct
injection of ‘naked’ messenger RNA (mRNA) into the skeletal
muscle of a mouse resulted in expression of the encoded protein,
development of mRNA vaccines was considered unrealistic be-
cause of the expected mRNA instability during storage and after
application in vivo. These concerns were compounded by difficul-
ties in manufacturing at large scale and lack of commercial sup-
pliers of high quality mRNA products. These concerns could be
resolved in recent years and the two current major applications of
syn-mRNAs with clinical potential are outlined in Fig. 1.
Highly specific and efficient vaccination can be achieved by the
Wolff approach with injection of ‘naked mRNA’, but the alterna-
tive route via ex vivo transformation of isolated autologous den-
dritic cells (DC) offers multiple advantages [4–8] and it is outlined
in Fig. 1A. The structural mRNA requirements for these applica-
tions are shown in Fig. 2A.
More recently, Warren et al. [9] have demonstrated the success-
ful mRNA-mediated reprogramming of human fibroblasts to in-
duced pluripotent stem cells (iPSC) and in turn, their mRNA-
mediated differentiation to the desired mature cell type. This route
is outlined in Fig. 1B and the more challenging structural mRNAwww.elsevier.com/locate/nbt
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FIGURE 1
Outline of two applications of syn-mRNAs with clinical potential. (A) Syn-mRNA-based vaccination via ex vivo transformation of isolated autologous dendritic cells.
(B) Syn-mRNA mediated reprogramming of human fibroblasts to induced pluripotent stem cells (iPSC) and their subsequent, mRNA-mediated differentiation to
the desired cell type.
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more, very stringent purification procedures by HPLC are advan-
tageous, and the standard procedure with silica-based spin column
purification is not always sufficient, possibly the removal of minor
amounts of short double stranded RNA fragments is critically
important for further reduced immune response, Kariko et al.
[10]. Possibly, future projects based on this mRNA approach could
provide additional power to the clinical application of iPSC,
considering the already initiated clinical study of the treatment
for age-related macular degeneration using iPSC, where a protein-
based route is used, Cyranoski [11].
In essence: activity and clearance of syn-mRNAs provide all
advantages of conventional pharmaceutical drugs, but avoid bio-
degradation and other environmental problems of synthetic
chemical drugs because syn-mRNAs do not contain non-biological
structures.
However, for cell biology laboratories, the generation of syn-
mRNA remains a severe limitation, especially if many different
constructs are needed in small scales at early stages of a project.
Another challenge comes later, if bigger amounts with high and
highly reproducible quality are needed or if regulatory require-
ments demand standardized and controlled manufacturing pro-
cesses in compliance with cGMP principles. Commercial suppliers
who meet these requirements are rare, GMP-grade mRNAs are
offered by two established companies [4]: Asuragen in the USA
and CureVac in Europe. A flexible small company like AmpTec
GmbH could be beneficial by offering all manufacturing options,
combined with flexible services for multiple sequences in small
amounts at early project stages and for large amounts at later
stages.
Design of syn-mRNAs
Syn-mRNAs present the advantage that their production can be
engineered to the required scale, and once the technology is
established it works, in principle, for all possible RNA sequences,
and there are essentially no size limitations. RNA sequences can be
adapted to the specific needs, concerning stability and translation
efficiency, which can be controlled or optimized by cis-acting
structural elements in the RNA: the 50-cap (structural and modified
alternatives are commercially available), the poly(A)-tail (defined230 www.elsevier.com/locate/nbtlength and absence of 30-terminal ‘masking’ sequences are possi-
ble), untranslated regions and the sequence of the coding region
can be optimized for the cellular background, and if needed,
nucleotide modifications can be inserted, Warren et al. [9]. For
discussions of the general design aspects we refer to several recent
reviews [5–8]. Requirements in the syn-mRNA structures and
quality control aspects are discussed in more detail in section
‘Structural and quality requirements for syn-mRNAs’.
Syn-mRNAs and cellular immune response: an
advantage or a problem?
Syn-mRNAs are recognized as non-self nucleic acids leading to
adaptable activation of the innate immune system [12]. Non-self
RNAs naturally originate from invading viruses or other cellular
pathogens and encode noncellular genes. This means, differentia-
tion between self and non-self RNAs are fundamental cellular
protective mechanisms against infections. Cells of the innate
immune system possess multiple sensory receptors that are acti-
vated by RNA, including Toll-like receptors (TLR) 3, 7, and 8, as
well as RIG-I-(retinoic acid-inducible gene I)-like receptors (RLR).
They differ in their cellular localization and ligand specifications,
and induce various complex signaling cascades that finally lead to
an antiviral state [13,14]. This state means a translational shut-
down, an up-regulation and production of interferons (IFNs) and/
or cell death [15]. These sensors detect the externally introduced,
in vitro transcribed mRNA-based therapeutics, and consequently
induce an analogous antiviral state [16].
Dependent on the therapeutic or scientific application, this
immune response can be beneficial or detrimental!
Innate immune response as an advantage
This immune response is beneficial in applications of mRNA-based
vaccinations, because it potentiates the immune response of the
vaccine itself. The syn-mRNA does not only encode the antigen
but it also acts as an adjuvant by enhancing immunological
responses and antigen presentation. Therefore, the use of syn-
mRNA is a rapidly growing field for vaccination strategies in the
battle against viral infections and cancer.
Several clinical applications based on syn-mRNA vaccination
are under investigation with a focus on DC [17,18]. DCs have a
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FIGURE 2
General structural requirements for syn-mRNAs. (A1) Desired structure for syn-mRNA for vaccination: 50-cap (the ARCA analogue) and a long, free 30-poly(A), and
no internal nucleotide modifications. (A2) Undesired features are crossed out: 50-terminal phosphates and a masked 30-terminal poly(A) with extra nucleotides,
indicate as V (=G, C or U). (A3) undesired, but accepted 50-OH, resulting from phosphatase treatment. (B1) Desired structure for syn-mRNA for cellular
reprogramming: 50-cap (the ARCA analogue) and a long, free 30-poly(A), and 100% replacement of all pyrimidines. Please note that other pyrimidine modifications
and modification levels can be used, see sections ‘Special highly modified mRNA constructs may overcome immunogenicity problems in cell culture systems’ and
‘Additional challenges in systemic gene therapy applications’. (B2) as B1, but with accepted 50-OH, resulting from phosphatase treatment.
www.elsevier.com/locate/nbt 231
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ercentral function in presenting antigens through major histocom-
patibility complex (MHC) class I and II proteins and in eliciting
both cellular and humoral immune responses. Immune responses
can be induced by loading DCs with proteins, cDNAs or mRNAs.
Although whole cell protein extracts can be used, the practicability
is limited by risks of including tumorigenic compounds and the
presence of many irrelevant antigens can cause autoimmune
responses. Using specific proteins is challenging. Therefore,
nucleic acid vaccinations present an interesting alternative. Fur-
thermore, genetic vaccinations against infectious diseases elimi-
nate the risk of mutation and uncontrollable proliferation of
inactivated pathogens. In principle, DNA can be taken up and
expressed by cells in vivo (or in vitro), its use as nucleic acid vaccine
has disadvantages, as mentioned before: DNA can integrate into
the host genome, causing inactivation of cellular genes or onco-
genesis. As a further disadvantage in this application, DNA results
in a long duration of expression of immunizing antigens, whereas
it has been demonstrated that optimal vaccination can be
achieved by a boost in antigen expression, as obtained by vacci-
nation with mRNA [19]. As outlined in Fig. 1A, the ex vivo route of
syn-mRNA-based immunotherapy starts with transfection of
(mostly autologous) human DCs.
Although most studies using syn-mRNA vaccination strategy
are directed towards immunotherapeutic treatment of different
cancers, already in 1993 Martinon et al. have demonstrated the
potential of a liposome-entrapped mRNA vaccine against influen-
za in a mouse model [20]. An extensive and updated study was
published in 2012 by Petsch et al. [6]. Also studies with HIV-1-
infected patients were initiated [21,22].
A helpful application could emerge with ‘mRNA vaccination as
a safe approach for specific protection from type I allergy’ [23]
using a broad panel of allergen-encoding syn-mRNA vaccines
which elicit long-lasting protection from sensitization, and induce
a type of immunity similar to the natural protective response that
is acquired in the presence of allergen burden early in life.
Innate immune response as a problem
Apart from vaccination, induced innate immune effects are detri-
mental for most other applications. For the production of high
amounts of recombinant proteins, translational shutdown is ob-
viously counterproductive, and repetitive RNA transfer for im-
proved productivity is obviously impossible after cell death.
However, low transformation efficiencies necessitate multiple
RNA transfer steps for successful conversation of one cell-type to
another, for example, in the generation of iPSC.
In scientific studies which address signaling pathways, the secre-
tion of IFN will trigger signaling cascades that can cause a mix-up
with the studied mRNA-related effects. In these cases, overcoming
the hurdles of immunogenic side effects is crucial for success.
Special highly modified mRNA constructs may overcome
immunogenicity problems in cell culture systems
It is frequently overlooked that eukaryotic mRNAs are extensively
modified in vivo, and it has been shown that mRNA containing
base-modified nucleosides lead to reduced signaling by the ssRNA
sensor RIG-I, and reduced induction of protein kinase R (PKR), a
global repressor of protein translation, and of the endosomal
ssRNA sensors TLR7 and TLR8 [24–27].232 www.elsevier.com/locate/nbtIn addition, it is known that 50-terminal triphosphates in mRNA
transcripts can trigger PKR [26] and RIG-I [28,29]. The standard
synthetic IVT-RNA products have a 50-triphosphate. Whereas the
50 ends of cellular mRNAs are modified post-transcriptionally in
the nucleus with a methylated m7GpppN cap structure which is
important for mRNA splicing, stabilization, transport and for
efficient protein synthesis by recruiting ribosomes. In essence,
the cap structure is mandatory for normal mRNA function. Ac-
cordingly, also syn-mRNAs require a 50-cap structure. Although
post-transcriptional capping in vitro is a possibility for achieving
very high capping efficiencies, the widely used strategy relies on
co-transcriptional capping by the addition of excess amounts of
synthetic cap structures. However, the chain-elongating GTP must
be present and it competes with the cap structure in the initiation
step, accordingly it is impossible to prevent that a significant
fraction of uncapped in vitro transcription (IVT) products with
50-triphosphates remains.
Recently, Warren et al. [9] addressed both aspects: (i) generating
highly modified mRNAs with complete replacement of both pyr-
imidines, m5C instead of C and C (Pseudo-U) instead of U; and (ii)
removing remaining 50-triphosphates by treating the syn-mRNAs
with a phosphatase. Furthermore, they used polymerase chain
reaction (PCR) products as IVT templates which encode a long,
free 30-terminal poly(A) tail with A120. A very detailed presenta-
tion of the technical procedures was provided by Mandal and Rossi
[30], including the identification of crucial steps and a trouble
shooting guide, see also below, section ‘Quality control aspects for
syn-mRNAs are illustrated in the following list for syn-mRNAs
from AmpTec’ (sections ‘Molecular purity’ and ‘Bioburden’).
From a biophysics perspective, the high frequency introduction
of 100% C has effects on the properties of these highly modified
syn-mRNAs. For example, one single C at a crucial position in a
tRNA anticodon has an important consequence: the tRNATyr with
its GCA anticodon does not only recognize the Tyr codons UAC
and UAU, but in addition, it can act as a natural suppressor of the
UAG stop codon, possibly due to a more rigid local RNA structure
and the stabilized central C:A base pair [31].
Although these highly modified syn-mRNAs dramatically atten-
uated interferon signaling, residual upregulation of some interfer-
on targets was still detected. The additional media
supplementation with recombinant B18R protein, a Vaccinia virus
decoy receptor for type I interferons, allowed for high, dose-
dependent levels of protein expression with high cell viability.
With the combination of RNA modifications with the B18R
interferon inhibitor, Warren et al. [9] have developed a technology
to overcome innate antiviral responses, and this enables highly
efficient reprogramming of somatic cells to pluripotency and
subsequently to direct the differentiation of pluripotent cells
towards a desired cell type.
It is important to note that modified syn-mRNA-derived iPSC
clones ‘more faithfully recapitulated the global transcriptional
signature of human ESCs than retrovirally derived iPSCs’. In
consequence, this route ‘may produce higher-quality iPSCs, possi-
bly owing to the fact that they are transgene free’.
In addition to ‘conventional’ mRNAs that encode only one
protein, Yoshioko et al. [32] present a different approach by
utilizing a single noninfectious (nonpackaging), self-replicating
Venezuelan equine encephalitis (VEE) virus RNA replicon that is
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and SOX2, with c-MYC or GLIS1). The required very long tran-
scripts (up to 15,000 nt) were obtained with standard commercial
IVT kits. No internal nucleoside modifications were introduced
and 50-capping was achieved post-transcriptionally by using a
high-efficiency enzymatic capping system. Expression of this un-
modified VEE-RNA was achieved but it was critically dependent on
high levels of the interferon inhibitor B18R.
As shown by Kariko et al. [10], dependence on the interferon
inhibitor supplement is at least reduced, if very stringent purifica-
tion procedures by HPLC are applied as an additional, final syn-
mRNA production step. Possibly, the removal of minor amounts of
short double stranded RNA fragments is critically important to
achieve this further reduced immune response.
Interesting to note: although 100% replacements of uridine by
C and cytidine by m5C were used by Warren et al. [9] for cellular
reprogramming, Yoshioko et al. [32] have used reduced levels with
only 25% of C and 25% of m5C.
Additional challenges in systemic gene therapy applications
Although the combination of RNA modifications with the B18R
interferon inhibitor is a viable possibility in cell culture systems,
this requirement could be a severe limitation for emerging sys-
temic applications in gene therapy and for engineered protein
expression changes in cellular targets [33].
In mouse model systems this limitation was not evident and
potential therapeutic applications for syn-mRNA in vivo could be
demonstrated. Rudolph and Kormann [34,35] have used a mouse
model for a lethal congenital lung disease that lacks surfactant
protein B (SP-B) expression in the pulmonary epithelium. Local
application of an aerosol with SP-B syn-mRNA resulted in high-
level SP-B expression and survival of the treated animals.
In addition to this localized use, systemic expression of biologi-
cally active erythropoietin protein in mice was achieved by injec-
tion of erythropoietin-encoding syn-mRNA into the tibalis
anterior, Kormann et al. [34], or into the peritoneal cavity, Kariko
et al. [36].
Important note for syn-mRNA constructs: 100% replacements
of uridine by C and cytidine by m5C as used by Warren et al. [9] for
cellular reprogramming are not always required: As already noted
above (section ‘Special highly modified mRNA constructs may
overcome immunogenicity problems in cell culture systems’),
Yoshioko et al. [32] have used reduced levels with only 25% of
C and m5C; Kariko et al. [36] maintained 100% level of C in a
combination with unmodified cytidine; Rudolph and Kormann
[34,35] have even shown potential advantages of using lower, 25%
modification levels with a combination of s2U and m5C.
Structural and quality requirements for syn-mRNAs
Optimized syn-mRNA constructs combine these structural fea-
tures (see also Fig. 2):
50-End
Standard IVT-RNAs carry a 50-triphosphate structure, whereas
cellular mRNAs have a 50-cap structure. In IVT reactions, the
cap structure can be added by an efficient post-transcriptional
enzymatic step, although capping is frequently introduced co-
transcriptionally by including a free cap structure GpppG whichcompetes with the standard nucleoside triphosphate pppG in the
transcription initiation step. But the natural cap includes a meth-
ylated G, with the structure m7GpppG. Its incorporation in IVT
products will lead to two different orientations: m7GpppGpN. . .. . .
and Gpppm7GpN. . ., and only 50% of the IVT product carry the
first, biologically active orientation. Several options are possible to
block the undesired elongation at m7G, with the Anti-Reverse Cap
Analogue (ARCA) as the most popular one. Here the 30-OH group
next to m7G is replaced by –OCH3, which prevents elongation and
directs IVT initiation to the desired opposite side. The ARCA
structure can be abbreviated as m7G(m)pppG (commercially avail-
able for example from life technologies, NE Biolabs, Trilink and
Jena Bioscience). But incorporation is usually only about 80% and
any remaining 50-triphosphates have to be carefully eliminated by
a phosphatase treatment of the purified IVT product.
30-End
Stable, fully functional cellular mRNAs have a long, free 30-termi-
nal poly(A) tail. A designed plasmid template for IVT can include a
long homopolymeric stretch of A’s but the maintenance of its
exact length during amplification in Eschrichia coli cells is difficult
to control. In addition, the generation of IVT templates by cleav-
ing at a standard restriction site following the poly(A) stretch,
leaves several non-A nucleotides, which in effect are masking the
poly(A) tail and intracellular mRNA efficiency can be twofold
reduced [5]. A possible bypass is the use of a class IIS restriction
enzyme where cleavage site and recognition sequence are separat-
ed [5], but their shorter recognition sequences can be problematic
if the same sequence is present within the mRNA sequence.
AmpTec takes a different approach for IVT template synthesis,
by generating PCR products which span the plasmid insert, as
outlined in Fig. 3. These IVT templates avoid both problems, the
length of the 50-terminal homopolymeric T-stretch in the chemi-
cally synthesized PCR primer is well defined, the PCR amplifica-
tion process is highly reproducible and there is no interference
with internal mRNA sequences. As indicated in Fig. 2, the standard
AmpTec primers introduce a 30-terminal poly(A) tail with 120 A’s.
Internal sequence
Requirements for 50- and 30-terminal structures are the same for all
mRNA applications, but for avoiding the innate immune response,
internal pyrimidines have to replaced. A substitution of CTP by
m5CTP and UTP by CTP (Pseudo-UTP) can achieve this goal. In
general, the modified NTPs are efficient substrates for T7 RNA
polymerase, comparable with their unmodified counterparts; ab-
errant premature termination can be avoided and full-size IVT
products are obtained (example in Fig. 4).
Although 100% replacement of uridine by C and cytidine by
m5C in mRNAs results in the described advantages, Rudolph and
Kormann [34,35] have shown potential benefits of using lower
modification levels.
Quality control aspects for syn-mRNAs are illustrated in the
following list for syn-mRNAs from AmpTec
Identity
Syn-mRNA sequences can be freely designed by the user, and they
are generated by the assembly of chemically synthesized sequence
blocks, which are inserted into a plasmid backbone and propagatedwww.elsevier.com/locate/nbt 233
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FIGURE 3
AmpTec approach for generating an insert-spanning PCR product as
template for IVT production of syn-mRNAs. A plasmid clone contains the
desired insert gene sequence and an insert-spanning PCR product is
obtained with a plasmid-based primer upstream of the T7 promoter (for
example M13 fwd) and a second primer (indicated as 50-T120) which combines
a hybrising 30-terminal gene-specific sequence with a long 50-terminal T120.
The resulting Tail-PCR product encodes a free poly(A) tail (sequence shown in
the IVT orientation), and the syn-mRNA product is obtained by IVT reactions,
which include a cap analogue and the desired NTP mixture with four
unmodified NTPs or a mixture of ATP, GTP, 100% m5CTP and 100% CTP; also
other modifications and modification levels are available.
FIGURE 4
Electropherogram of IVT-RNAs. IVT reactions with T7 RNA polymerase were
performed with standard, unmodified NTPs (red tracing) or with an NTP-
mixture containing ATP, GTP, 100% m5CTP, 100% CTP (blue tracing). After
spin column purification, capillary electrophoresis was performed with
Agilent 2100 Bioanalyzer using the RNA 6000 Nanochip.
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sequenced and must have 100% identity with the expected
sequence.
To generate a template for IVT reactions with T7 RNA polymer-
ase, plasmid DNA is converted to an insert-specific PCR product
which includes a long terminal stretch of 120 T’s. Two options are
available for 50-capping: Post-transcriptional addition with a cap-
ping enzyme or co-transcriptional by including an excess of a cap
analogue, which competes with GTP, the standard IVT initiator.
With about 80% efficiency in co-transcriptional capping, any
remaining 50-terminal triphosphates must be removed by a phos-
phatase treatment, subsequent to the spin column purification of
IVT products.
Capillary electrophoresis (Agilent Bioanalyzer 2100 or TapeSta-
tion 2200) is used to verify the correct mRNA size and prove that
the expected syn-mRNA is the major product. Optionally, suscep-
tibility to RNase can be used as additional verification of molecular
identity.
Routinely, users can select a set of important gene sequences
which must be absent in the syn-mRNA product. With the use of234 www.elsevier.com/locate/nbtcapillary electrophoresis as analytical tool, the expected sizes of
undesired RNAs must be significantly different from the syn-
mRNA product, but the limits of detection are only in the %
range. AmpTec employs reverse transcription polymerase chain
reaction (RT-PCR) as an additional analytical approach to avoid
dependence on size differences and for increased sensitivity: gene-
specific RT-PCR assays for all user-selected sequences are combined
with capillary electrophoresis (Agilent) of the resulting RT-PCR
products. In this manner, detection sensitivities in the parts per
million (ppm) range are achieved. These assays are performed at
two stages in the manufacturing process: as PCR with the starting
material, plasmid DNA, and as RT-PCR with the final product, syn-
mRNA.
Quantification
Standard measurements by UV absorbance at 260 nm are performed
in a defined buffer (10 mM TE buffer, pH 8). Variability due to
hypochromicity (random effects in the formation of aberrant
RNA conformations with double-stranded regions) is reduced by
a heat renaturation step. The combination with capillary electro-
phoresis (Agilent) provides an independent quantification method.
As a special option, quantification by HPLC is offered: the RNA
is completely digested with nuclease P1 and the resulting nucleo-
side monophosphates are analyzed. In addition to an absolute
RNA quantification, this provides quantitative base composition
ratios and enables a comparison with the sequence-predicted
values; furthermore, the quantitative insertion of modified
nucleotides can be monitored.
Molecular purity
Residual proteins, bacterial genomic DNA, bacterial RNA, and endo-
toxin must be below specified limits. The work-flow of AmpTec
already includes the use of minimal amounts of bacterial-derived
New Biotechnology Volume 32, Number 1  January 2015 RESEARCH PAPER
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a million-fold lower than in protocols where plasmid DNA is directly
used as IVT template. This level of plasmid-derived material is about
100-fold lower, as compared with the work-flow described by Man-
dal and Rossi [30]. In addition to reducing carry-over of bacterial
compounds, this also eliminates the need of using a linearized
plasmid as template for Heel-PCR.
The presence of residual template DNA is checked. As explained
above, AmpTec employs RT-PCR assays, combined with capillary
electrophoresis (Agilent) of PCR products. An additional Minus-RT
control can detect residual template DNA with a sensitivity in the
ppm range.
Further option: In addition to analytic HPLC (see section
‘Quantification’), HPLC can be applied as a final purification step
to achieve higher purity in general, and for increased sample
homogeneity by removing undesired shorter or longer IVT
products.Bioburden
Endotoxin-level is monitored and sterility is controlled by stan-
dard microbiological assays (aerobic, anaerobic, fungi). This aspect
was only indirectly addressed in the detailed work-flow of Mandal
and Rossi [30] as potential problem of ‘RNA toxicity’ in their
troubleshooting section.
Concluding remarks and outlook
This short overview has presented encouraging advancements in
the generation of syn-mRNA molecules, paving the way for the
now rapidly growing applications.
Challenges remain in the further optimization of the syn-mRNA
construct itself and of standardized, efficient methods to obtain
stable syn-mRNA preparations, and in developing novel formula-
tions to achieve efficient cell entry and intracellular activity,
ideally with the option to engineer different versions with selec-
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